Blinatumomab Treatment Guidelines

Introduction to Blinatumomab Adverse Events

Blinatumomab treatment is associated with two major serious adverse events: neurologic toxicities (occurring in up to 50% of patients) and cytokine release syndrome (CRS), both of which require close monitoring and prompt intervention in a specialized cancer center with experience administering this medication 1, 2

Neurologic toxicities occur in up to 50% of patients, with a median onset at 7 days after starting treatment, and grade 3 or higher neurologic toxicities occur in 15% of patients 1, 2
The manifestations of neurologic toxicities include encephalopathy, convulsions/seizures, disorientation, neurotoxicity, agnosia, intention tremor 1, 2

CRS typically occurs within the first 2 days after starting blinatumomab infusion, with manifestations including pyrexia (fever), headache, nausea, asthenia (weakness), hypotension, increased transaminases, and increased total bilirubin 1, 2
The risk factors for CRS include higher disease burden, first cycle of treatment, and higher doses 1, 2

Prevention strategies include administering blinatumomab in specialized cancer centers with experience using the medication, using stepwise dosing, and monitoring closely for early signs of toxicity 1
Intervention for neurologic toxicities includes early recognition, prompt intervention, dose interruption or discontinuation for severe cases, and supportive care 1, 2
Intervention for CRS includes early recognition, prompt intervention, and the use of tocilizumab (IL-6 receptor antagonist) for severe cases, as well as dexamethasone for severe symptoms 1, 2

Pre-treatment assessment includes evaluating pre-existing neurological conditions, reviewing concomitant medications, and assessing baseline liver function and blood counts 1, 2
Continuous monitoring is required during the first 48 hours of treatment for CRS, and daily neurologic assessment is necessary from days 3-14 for neurologic toxicity 1, 2
Regular monitoring of liver function tests, complete blood counts, and assessment for signs of infection are necessary throughout treatment 1, 2

The National Comprehensive Cancer Network recommends that blinatumomab should be used with caution in pregnancy, as it may cause fetal harm, and breastfeeding should be avoided during treatment and for 48 hours after the last dose 1, 2